BeyondSpring is a clinical-stage biopharmaceutical company. It develops immuno-oncology cancer therapies and offers a drug development pipeline which includes a variety of Plinabulin products. The company also provides a preclinical immuno-oncology pipeline that includes BPI-002, BPI-003, and BPI-004 programmes.
|HQ||New York, US||Map|
|Employees (est.) (Dec 2018)||52||(+37%)|
|Share Price (Nov 2019)||$12.5||(-4%)|
Net income (H1, 2019)
EBIT (H1, 2019)
Market capitalization (29-Nov-2019)
Closing stock price (29-Nov-2019)
|Acquired Company||Date||Deal Size|
|Beijing Wanchun Pharmaceutical Technology|
|BeyondSpring (HK) Limited|
|BeyondSpring Pharmaceuticals Inc.|
|BeyondSpring Pharmaceuticals Australia PTY|
|Dalian Wanchunbulin Pharmaceuticals Ltd.|
|Wanchun Biotechnology Limited|
|Wanchun Biotechnology (Shenzhen) Ltd.|
BeyondSpring has 51 Twitter Followers. The number of followers has increased 0.5% month over month and increased 10.2% quarter over quarter
When was BeyondSpring founded?
BeyondSpring was founded in 2010.
Who are BeyondSpring key executives?
BeyondSpring's key executives are Lan Huang, Ramon Mohanlal and Richard Daly.
How many employees does BeyondSpring have?
BeyondSpring has 52 employees.
Who are BeyondSpring competitors?
Competitors of BeyondSpring include TESARO, Omeros and Athersys.
Where is BeyondSpring headquarters?
BeyondSpring headquarters is located at 28 Liberty St 39th Floor, New York.
Where are BeyondSpring offices?
BeyondSpring has an office in New York.
How many offices does BeyondSpring have?
BeyondSpring has 1 office.
Receive alerts for 300+ data fields across thousands of companies